Приказ основних података о документу
Unique pipeline for the assessment of novel genetic variants leads to confirmation of PCD diagnosis
dc.creator | Stevanović, Nina | |
dc.creator | Anđelković, Marina | |
dc.creator | Skakić, Anita | |
dc.creator | Spasovski, Vesna | |
dc.creator | Stojiljković, Maja | |
dc.creator | Parezanović, Marina | |
dc.creator | Ugrin, Milena | |
dc.creator | Pavlović, Sonja | |
dc.date.accessioned | 2023-12-15T09:46:29Z | |
dc.date.available | 2023-12-15T09:46:29Z | |
dc.date.issued | 2023 | |
dc.identifier.uri | https://imagine.imgge.bg.ac.rs/handle/123456789/2275 | |
dc.description.abstract | Background/Objectives: Primary ciliary dyskinesia (PCD) is a disease caused by impaired ciliary motility and mainly affects the lungs and reproductive organs. Inheritance is autosomal recessive and X-linked with more than 40 disease-causing genes, wherefore PCD patients have diverse clinical manifestations, thus making diagnosis difficult. The utility of next-generation sequencing (NGS) technology for diagnostic purposes allows a better understanding of the PCD genetic background. However, the identification of specific disease-causing variants is challenging. The objective of this study was to create a unique guideline that will enable the standardization of the assessment of novel variants within PCD associated genes. Methods: The study included designing a pipeline for the classification of the rare genetic variants detected using NGS. The pipeline included in silico (translation, 3D-model, protein-protein interactions, sequence conservation, posttranslational modifications) and functional analysis (expressional analysis, Western Blot) of the variants. Results: The designed pipeline consists of three steps: sequencing, detection, and identification of genes/variants; classification of variants according to their effect; and variant characterization using in silico structural and functional analysis. The pipeline was validated by the analysis of the variants detected in a disease-causing gene (DNAI1) and the novel candidate gene (SPAG16). Conclusion: The application of the pipeline resulted in the identification of disease-causing variants, as well as pathogenicity validation, through the analysis on transcriptional, translational, and posttranslational levels.The application of created pipeline leads to the confirmation of PCD diagnosis and enables a shift from candidate to disease-causing gene. | sr |
dc.language.iso | en | sr |
dc.publisher | Springer Nature | sr |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200042/RS// | sr |
dc.rights | openAccess | sr |
dc.source | European Journal of Human Genetic | sr |
dc.title | Unique pipeline for the assessment of novel genetic variants leads to confirmation of PCD diagnosis | sr |
dc.type | conferenceObject | sr |
dc.rights.license | ARR | sr |
dc.citation.epage | 383 | |
dc.citation.issue | Supplement S1 | |
dc.citation.spage | 383 | |
dc.citation.volume | 31 | |
dc.description.other | Abstracts from the 55th European Society of Human Genetics (ESHG) Conference | sr |
dc.identifier.doi | 10.1038/s41431-023-01338-4 | |
dc.identifier.fulltext | https://imagine.imgge.bg.ac.rs/bitstream/id/528635/bitstream_528635.pdf | |
dc.type.version | publishedVersion | sr |